Abstract
Clozapine has been described as the “gold standard” therapy for treatment-resistant schizophrenia, causing fewer extra pyramidal side-effects than when first generation antipsychotics are used. It has also proved beneficial in treatment-resistant agitation in patients with dementia. Clozapine pharmacotherapy is reported to be of the low fatality rate has been attributed to clinical monitoring systems. It can lead however to potentially fatal agranulocytosis or myocarditis/cardiomyopathy as well as to a myriad of less severe side effects.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
